Stocks · News reference
Stoke Therapeutics Says FDA Willing To Accept Planned Phase 3 Cognition And Behavior Analysis For Zorevunersen In Dravet Syndrome
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
JP Morgan Upgrades Biogen to Overweight, Raises Price Target to $300
JP Morgan analyst Chris Schott upgrades Biogen (NASDAQ:BIIB) from Neutral to Overweight and raises the price target from $210 to $300.
Biogen shares are trading higher after UBS maintained its Buy rating and raised its price target on the stock from $240 to $270.
UBS Maintains Buy on Biogen, Raises Price Target to $270
UBS analyst Michael Yee maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $240 to $270.
Stoke Therapeutics Presents Data For STK-002 Supporting Disease-Modifying Potential In Autosomal Dominant Optic Atrophy At AAO 2026 Annual Meeting
–ADOA is the most common inherited optic nerve disorder and is primarily caused by variants in the OPA1 gene that result in insufficient levels of OPA1 protein, leading to progressive and irreversible vision
8-K filing — Stoke Therapeutics, Inc. (STOK)
Filed: 2026-09-25 AccNo: 0001193125-26-402820 Size: 137 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers